A new biomarker in lung cancer

After screening for transactivated genes in non-small cell lung cancer (NSCLC) tissue samples, researchers at the University of Tokyo have identified chondrolectin as a potential lung cancer biomarker. In vitro studies suggested a strong association with shorter survival and a link with cancer cell growth and invasive activity. This could be useful as a diagnostic or prognostic biomarker, and as a potential target for drug development. Abstract

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.